Modified KSA and Uses Thereof
The present invention relates to a nucleic acid encoding a polypeptide and the use of the nucleic acid or polypeptide in preventing and/or treating cancer. In particular, the invention relates to improved vectors for the insertion and expression of foreign genes encoding tumor antigens for use in immunotherapeutic treatment of cancer.
1 - 39 . (canceled)
40 . An expression vector useful for immunizing a host comprising nucleic acid sequences encoding modified KSA.
41 . The expression vector of claim 40 wherein the vector is a plasmid or a viral vector.
42 . The expression vector of claim 41 wherein the viral vector is selected from the group consisting of poxvirus, adenovirus, retrovirus, herpesvirus, and adeno-associated virus.
43 . The expression vector of claim 42 wherein the viral vector is a poxvirus selected from the group consisting of vaccinia, NYVAC, avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
44 . The expression vector of claim 43 wherein the viral vector is a poxvirus selected from the group consisting of NYVAC, ALVAC, and ALVAC(2).
45 . The expression vector of claim 40 further comprising at least one additional tumor associated antigen.
46 . The expression vector of claim 45 wherein the tumor associated antigen is selected from the group consisting of carcinoembryonic antigen, a modified carcinoembryonic antigen, or p53.
47 . The expression vector of claim 40 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
48 . The expression vector of claim 47 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
49 . A composition comprising an expression vector of claim 40 in a pharmaceutically acceptable carrier.
50 . A method for preventing or treating cancer comprising administering to a host a composition of claim 49 .
51 . An isolated DNA molecule encoding SEQ ID NO.: 15.
52 . An expression vector comprising SEQ ID NO.: 4 and p53 as shown in SEQ ID NO.: 2.
53 . The expression vector of claim 52 further comprising SEQ ID NO.: 20.
54 . The expression vector of claim 52 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
55 . The expression vector of claim 53 further comprising at least one nucleic acid sequence encoding a co-stimulatory component.
56 . The expression vector of claim 54 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
57 . The expression vector of claim 55 wherein the co-stimulatory component is selected from the group consisting of B7.1, LFA-3 and ICAM-1.
58 . A method for preventing or treating cancer comprising administering to a host an expression vector of claim 52 .
59 . A method for preventing or treating cancer comprising administering to a host an expression vector of claim 53 .